Neuroscience Letters 1996-08-23

Effect of a pyridinium metabolite derived from haloperidol on the activities of striatal tyrosine hydroxylase in freely moving rats.

K Igarashi, K Matsubara, F Kasuya, M Fukui, T Idzu, N Castagnoli

Index: Neurosci. Lett. 214(2-3) , 183-6, (1996)

Full Text: HTML

Abstract

The effects of a pyridinium metabolite (HPP+) derived from haloperidol (HP) on in vivo tyrosine hydroxylation was evaluated in freely moving rats. As an index of the in vivo activity of tyrosine hydroxylase (TH), the rat striatum was perfused with NSD-1015, and extracellular 3,4-dihydroxyphenylalanine (DOPA) levels were measured. HPP+ (1 mM) gradually reduced tyrosine hydroxylation to 30% of the basal level, although the effect was less potent than 1-methyl-4-phenylpyridinium ion (MPP+). On the contrary, HPP+ at a 0.1 mM dose decreased in 5-hydroxyindoleacetic acid (5-HIAA) level, but did not affect dopamine metabolites. The present study revealed that HPP+ irreversible inhibited in vivo tyrosine hydroxylation by the same manner of MPP+. However, the neurotoxic effects of HPP+ in vivo would be selective for serotonergic over dopaminergic neurons, which distinguishes the toxic profile of this compound compared to that of MPP+.

Related Compounds

  • Haloperidol Metab...

Related Articles:

Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors.

2009-07-01

[Psychopharmacology 205 , 21-33, (2009)]

Determination of haloperidol and reduced haloperidol in human serum by liquid chromatography after fluorescence labeling based on the Suzuki coupling reaction.

2006-10-01

[Anal. Bioanal. Chem 386(3) , 719-24, (2006)]

Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.

1994-06-01

[Eur. Neuropsychopharmacol. 4(2) , 119-26, (1994)]

Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.

1999-07-01

[Int. Clin. Psychopharmacol. 14(4) , 219-28, (1999)]

Correlation of clinical response (PANSS) and plasma levels of haloperidol and reduced haloperidol in schizophrenia.

1994-03-01

[Prog. Neuropsychopharmacol. Biol. Psychiatry 18(2) , 347-53, (1994)]

More Articles...